Journal of Cutaneous Immunology and Allergy (Aug 2023)
Earlier continuous administration of mepolizumab for eosinophilic granulomatosis with polyangiitis based on cutaneous findings
Abstract
Earlier continuous administration of mepolizumab could be useful in controlling relapse and refractory disease of EGPA. The administration can reduce the need for less desirable treatment protocols such as long‐term corticosteroids.
